Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Change in Cash (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Change in Cash for 4 consecutive years, with -$913000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Cash fell 108.2% to -$913000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $3.2 million, a 274.87% increase, with the full-year FY2024 number at $11.9 million, up 132.24% from a year prior.
  • Change in Cash was -$913000.0 for Q3 2025 at Century Therapeutics, down from $4.9 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $69.6 million in Q1 2022 to a low of -$27.1 million in Q4 2022.
  • A 4-year average of $34133.3 and a median of -$1.4 million in 2022 define the central range for Change in Cash.
  • Peak YoY movement for Change in Cash: skyrocketed 221.99% in 2024, then plummeted 1183.79% in 2025.
  • Century Therapeutics' Change in Cash stood at -$27.1 million in 2022, then soared by 70.53% to -$8.0 million in 2023, then surged by 172.42% to $5.8 million in 2024, then plummeted by 115.79% to -$913000.0 in 2025.
  • Per Business Quant, the three most recent readings for IPSC's Change in Cash are -$913000.0 (Q3 2025), $4.9 million (Q2 2025), and -$6.6 million (Q1 2025).